CVS Health Co. (NYSE:CVS) Shares Sold by Raab & Moskowitz Asset Management LLC

Raab & Moskowitz Asset Management LLC trimmed its stake in shares of CVS Health Co. (NYSE:CVS) by 3.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,959 shares of the pharmacy operator’s stock after selling 622 shares during the quarter. Raab & Moskowitz Asset Management LLC’s holdings in CVS Health were worth $1,260,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CVS. Exchange Traded Concepts LLC grew its stake in CVS Health by 22.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,993 shares of the pharmacy operator’s stock worth $418,000 after purchasing an additional 1,112 shares in the last quarter. Advisory Alpha LLC increased its holdings in shares of CVS Health by 19.8% in the 3rd quarter. Advisory Alpha LLC now owns 3,674 shares of the pharmacy operator’s stock valued at $257,000 after acquiring an additional 606 shares during the last quarter. Benin Management CORP increased its holdings in shares of CVS Health by 1.7% in the 3rd quarter. Benin Management CORP now owns 36,074 shares of the pharmacy operator’s stock valued at $2,519,000 after acquiring an additional 600 shares during the last quarter. SOL Capital Management CO increased its holdings in shares of CVS Health by 17.0% in the 3rd quarter. SOL Capital Management CO now owns 47,217 shares of the pharmacy operator’s stock valued at $3,297,000 after acquiring an additional 6,871 shares during the last quarter. Finally, Coerente Capital Management increased its holdings in shares of CVS Health by 5.3% in the 3rd quarter. Coerente Capital Management now owns 208,704 shares of the pharmacy operator’s stock valued at $14,572,000 after acquiring an additional 10,550 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Down 0.2 %

CVS Health stock opened at $67.18 on Friday. CVS Health Co. has a twelve month low of $64.41 and a twelve month high of $83.25. The stock has a 50 day moving average of $74.42 and a two-hundred day moving average of $73.66. The company has a current ratio of 0.86, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $84.68 billion, a price-to-earnings ratio of 10.40, a PEG ratio of 0.89 and a beta of 0.52.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The company had revenue of $93.81 billion during the quarter, compared to analysts’ expectations of $90.58 billion. During the same period last year, the firm earned $1.99 EPS. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, research analysts expect that CVS Health Co. will post 8.31 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be issued a $0.665 dividend. The ex-dividend date is Friday, April 19th. This represents a $2.66 annualized dividend and a dividend yield of 3.96%. CVS Health’s dividend payout ratio is currently 41.18%.

Analysts Set New Price Targets

CVS has been the topic of a number of recent analyst reports. Royal Bank of Canada dropped their price objective on CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a report on Thursday, February 8th. Leerink Partnrs reiterated an “outperform” rating on shares of CVS Health in a report on Monday, February 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $87.00 price objective on shares of CVS Health in a report on Wednesday, April 10th. Wells Fargo & Company decreased their target price on CVS Health from $83.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 8th. Finally, SVB Leerink assumed coverage on CVS Health in a research report on Monday, February 26th. They issued an “outperform” rating and a $88.00 target price for the company. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $89.44.

Insider Activity

In other news, EVP Prem S. Shah sold 29,473 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $76.95, for a total value of $2,267,947.35. Following the completion of the sale, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.24% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.